Ji Zhang1, Dong Liu1, Bingqing Yue1, Le Ban1, Min Zhou1, Hongmei Wang1, Jian Lv1, Bo Wu1, Zhenguo Zhai2,3, Kai-Feng Xu4, Wenhui Chen5, Jingyu Chen1,5. 1. Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China. 2. Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China. 3. National Clinical Research Center for Respiratory Diseases, Peking University Health Science Center, Beijing, China. 4. Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing, China. 5. Department of Lung Transplantation, Center for Lung Transplantation, Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China.
Abstract
Background: Lymphangioleiomyomatosis (LAM) is a rare systemic disease that generally leads to a progressive decline in pulmonary function. Experience, especially from the Asian population, including combined drug therapy before and after lung transplantation (LT) in LAM, is still limited. This study aimed to summarize the clinical data from patients with pulmonary LAM who underwent LT at centers in China. Methods: A retrospective review of all patients with LAM undergoing LT at the two largest centers in China between 2010 and 2018 was conducted. Pre- and posttransplant data were assessed and analyzed. Results: Overall, 25 patients with LAM underwent bilateral LT. The mean age was 35.0 ± 8.6 years at diagnosis and 36.8 ± 9.3 years at the time of transplant. Before LT, only six patients could complete pulmonary function test; the reachable mean forced expiratory volume in one second (FEV1) before LT was 15.9 ± 6.9%. Twenty-one patients (84%) had a recurrent pneumothorax, four (16.0%) of which required pleurodesis. Eight patients (32%) were treated with sirolimus pretransplant for 3.9 years (1-9 years). The average intra-surgery bleeding volume was 1,280 ± 730 ml in need of a transfusion of 1,316 ± 874 ml due to moderate-to-severe adhesion and pretransplant pleurodesis. The causes of death of four patients (16%) included primary graft dysfunction, bronchial dehiscence with long-term use of sirolimus, and uncontrollable infections. The median follow-up time from LT was 41.1 ± 25.0 months. Conclusions: LT for LAM patients from the Asian population has been reinforced from the data that we presented. Peri-transplantation use of sirolimus and LAM-related complications should be further defined and under constant surveillance.
Background: Lymphangioleiomyomatosis (LAM) is a rare systemic disease that generally leads to a progressive decline in pulmonary function. Experience, especially from the Asian population, including combined drug therapy before and after lung transplantation (LT) in LAM, is still limited. This study aimed to summarize the clinical data from patients with pulmonary LAM who underwent LT at centers in China. Methods: A retrospective review of all patients with LAM undergoing LT at the two largest centers in China between 2010 and 2018 was conducted. Pre- and posttransplant data were assessed and analyzed. Results: Overall, 25 patients with LAM underwent bilateral LT. The mean age was 35.0 ± 8.6 years at diagnosis and 36.8 ± 9.3 years at the time of transplant. Before LT, only six patients could complete pulmonary function test; the reachable mean forced expiratory volume in one second (FEV1) before LT was 15.9 ± 6.9%. Twenty-one patients (84%) had a recurrent pneumothorax, four (16.0%) of which required pleurodesis. Eight patients (32%) were treated with sirolimus pretransplant for 3.9 years (1-9 years). The average intra-surgery bleeding volume was 1,280 ± 730 ml in need of a transfusion of 1,316 ± 874 ml due to moderate-to-severe adhesion and pretransplant pleurodesis. The causes of death of four patients (16%) included primary graft dysfunction, bronchial dehiscence with long-term use of sirolimus, and uncontrollable infections. The median follow-up time from LT was 41.1 ± 25.0 months. Conclusions: LT for LAM patients from the Asian population has been reinforced from the data that we presented. Peri-transplantation use of sirolimus and LAM-related complications should be further defined and under constant surveillance.
Authors: Khalid F Almoosa; Jay H Ryu; Jose Mendez; J Terrill Huggins; Lisa R Young; Eugene J Sullivan; Janet Maurer; Francis X McCormack; Steven A Sahn Journal: Chest Date: 2006-05 Impact factor: 9.410
Authors: J Moss; N A Avila; P M Barnes; R A Litzenberger; J Bechtle; P G Brooks; C J Hedin; S Hunsberger; A S Kristof Journal: Am J Respir Crit Care Med Date: 2001-08-15 Impact factor: 21.405
Authors: T N Machuca; M J Losso; S M Camargo; S M Schio; I A Melo; B Hochhegger; J C Felicetti; J J Camargo Journal: Transplant Proc Date: 2011 Jan-Feb Impact factor: 1.066
Authors: T M Egan; S Murray; R T Bustami; T H Shearon; K P McCullough; L B Edwards; M A Coke; E R Garrity; S C Sweet; D A Heiney; F L Grover Journal: Am J Transplant Date: 2006 Impact factor: 8.086
Authors: Jan Groetzner; Felix Kur; Fritz Spelsberg; Jurgen Behr; Lorenz Frey; Iris Bittmann; Michael Vogeser; Peter Ueberfuhr; Bruno Meiser; Rudolf Hatz; Bruno Reichart Journal: J Heart Lung Transplant Date: 2004-05 Impact factor: 10.247
Authors: Janet R Maurer; Jay Ryu; Gerald Beck; Joel Moss; Jar-Chi Lee; Geraldine Finlay; Kevin Brown; Jeffrey Chapman; June McMahan; Eric Olson; Stephen Ruoss; Susan Sherer Journal: J Heart Lung Transplant Date: 2007-12 Impact factor: 10.247
Authors: Melissa B King-Biggs; Jordan M Dunitz; Soon J Park; S Kay Savik; Marshall I Hertz Journal: Transplantation Date: 2003-05-15 Impact factor: 4.939